7 recruiting, 6 terminated, 5 completed, 2 not yet recruiting. 24 Phase 1, 9 Phase 2.
Follow Pediatric Cancer: new trials by email Literature Review of Pediatric Cancer trials Research Report on Pediatric Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors Zanzalintinib - Cancer, Pediatric Cancer | Phase 1 | Not yet recruiting | Exelixis | 18 | 2026-09-30 | 2026-08-19 |
| Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation Immediate Start - Virtual Reality, Delayed Start - Virtual Reality - Pediatric Cancer | Phase 1 | Completed | University of Alabama at Birmingham | 11 | 2024-06-27 | 2026-03-18 |
| Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen Pucotenlimab - Rhabdomyosarcoma, Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 82 | 2024-06-06 | 2024-06-13 |
| Lurbinectedin in FET-Fused Tumors Lurbinectedin - Ewing Sarcoma, Desmoplastic Small Round Cell Tumor | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 63 | 2023-07-27 | 2026-09-02 |
| Curcumin VS Photo-bio-modulation Therapy of Oral Mucositis in Pediatric Patients Undergoing Anti-Cancer Non-invasive Treatment Curcumin, Laser - Oral Mucositis, Pediatric Cancer | Phase 1 | Completed | Riyadh Elm University | 90 | 2023-03-15 | 2024-08-05 |
| Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients Atezolizumab, Sorafenib, Bevacizumab - Refractory Solid Tumor, Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 64 | 2022-11-07 | 2026-05-19 |
| Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML Uproleselan, Fludarabine, Clofarabine - Acute Myeloid Leukemia, Pediatric Cancer | Phase 1 | Terminated | Malika Kapadia | 1 | 2022-10-06 | 2024-08-19 |
| TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide Temozolomide Oral Suspension - Pediatric Cancer | Phase 1 | Completed | Orphelia Pharma | 49 | 2021-03-16 | 2025-07-31 |
| A Pilot Randomized Controlled Trial for Feasibility of Administering an AR Game to Postoperative Pediatric Cancer Patients ARISE with AR, ARISE without AR - Pediatric Cancer, Surgery | Phase 1 | Unknown | ALTality, Inc. | 20 | 2021-01-13 | 2021-08-16 |
| Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors Sintilimab - Pediatric Cancer | Phase 1 | Unknown | Sun Yat-sen University | 18 | 2020-08-11 | 2020-09-03 |
| Phase I Study of Marizomib + Panobinostat for Children With DIPG Marizomib, Panobinostat - Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma | Phase 1 | Terminated | Dana-Farber Cancer Institute | 4 | 2020-08-10 | 2024-02-15 |
| Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination - Pediatric Cancer | Phase 1 | Recruiting | Assistance Publique Hopitaux De Marseille | 54 | 2020-08-03 | 2026-11-12 |
| 9-ING-41 in Pediatric Patients With Refractory Malignancies. 9-ING-41, Irinotecan, Temozolomide - Refractory Cancer, Refractory Neoplasm | Phase 1 | Terminated | Actuate Therapeutics Inc. | 40 | 2020-06-05 | 2025-07-17 |
| A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3 - Solid Tumors, Hepatocellular Carcinoma (HCC) | Phase 1 | Recruiting | Chiome Bioscience Inc. | 66 | 2020-06-01 | 2026-06-17 |
| Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia Intravenous fluids - Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Virginia Commonwealth University | 10 | 2019-10-02 | 2024-02-13 |
| Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma Famitinib, Ifosfamide, Camrelizumab - Effect of Drugs, Progression | Phase 1 / Phase 2 | Withdrawn | Peking University People's Hospital | 2019-08-15 | 2020-05-19 | |
| A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia Tranexamic Acid, Normal saline - Pediatric Cancer, Thrombocytopenia | Phase 1 / Phase 2 | Terminated | Meghan McCormick | 11 | 2019-04-22 | 2021-09-20 |
| Durvalumab and Tremelimumab for Pediatric Malignancies Durvalumab / Tremelimumab Combination Therapy - Pediatric Cancer, Solid Tumor Pediatric | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 50 | 2019-03-07 | 2026-09-29 |
| Radiotherapy Delivery in Deep Inspiration for Pediatric Patients radiotherapy delivery in deep-inspiration - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Copenhagen University Hospital, Rigshospitalet | 25 | 2017-01-01 | 2020-10-09 |
Showing 20 of 24. Sign in to see all of them.
Neoplasms (24) · Carcinoma, Hepatocellular (3) · Neuroblastoma (3) · Recurrence (3) · Diffuse Intrinsic Pontine Glioma (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Rhabdomyosarcoma (2) · Sarcoma, Ewing (2) · Brain Neoplasms (1) · Burkitt Lymphoma (1) · Desmoplastic Small Round Cell Tumor (1) · Disease Progression (1) · Fibrolamellar hepatocellular carcinoma (1)
Neoplasms by Histologic Type (13) · Neoplasms by Site (7) · Hemic and Lymphatic Diseases (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Hematologic Diseases (5) · Neoplasms, Germ Cell and Embryonal (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Disease Attributes (4) · Neoplasms, Neuroepithelial (4) · Adenocarcinoma (3) · Brain Diseases (3) · Carcinoma (3)
Cyclophosphamide (3) · Dexamethasone (2) · Irinotecan (2) · Temozolomide (2) · Topotecan (2) · Vinorelbine (2) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · AZD 6244 (1) · Azacitidine (1) · Bevacizumab (1) · Busulfan (1) · CYC065 (1) · Calcium Dobesilate (1) · Carboplatin (1) · Clofarabine (1)
Sun Yat-sen University (2) · ALTality, Inc. (1) · Actuate Therapeutics Inc. (1) · AeRang Kim (1) · Assistance Publique Hopitaux De Marseille (1) · AstraZeneca (1) · BeOne Medicines (1) · Children's Hospital of Philadelphia (1) · Chiome Bioscience Inc. (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dana-Farber Cancer Institute (1) · Exelixis (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Malika Kapadia (1) · Meghan McCormick (1)
United States (12) · France (4) · China (3) · Netherlands (3) · Spain (3) · United Kingdom (3) · Denmark (2) · Germany (2) · Italy (2) · Finland (1) · Japan (1) · Saudi Arabia (1) · Sweden (1)
AeRang Kim, MD, PhD (1) · Amanda Linz, MD (1) · Ashok Gupta, MD, PhD (1) · Birgit Geoerger, MD (1) · Cady P Noda, PharmD (1) · Christina York (1) · Jae Eun Choi (1) · Jamie Sinton, MD (1) · Jessica Gartrell, MD (1) · Juan Cata, MD (1) · Katherine Warren, MD (1) · Malika Kapadia, MD (1) · Meghan McCormick, MD (1) · Per Kogner, Professor (1)
PMID 24327518, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29587881, PMID 29846250, PMID 31101621, PMID 31401903, PMID 31533931, PMID 31538815, PMID 31831767, PMID 31882719, PMID 32005489, PMID 33892407, PMID 34347542, PMID 34533416, PMID 34543871, PMID 35292802, PMID 37828033, PMID 39714090, PMID 39832211, PMID 39868759, PMID 41838385, PMID 42222420, PMID 42686334
2016 (1), 2018 (1), 2023 (1), R42DA050365 (1)